
## Geum-Youn Gwak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5484144/publications.pdf Version: 2024-02-01



| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular<br>Carcinoma. Gastroenterology, 2015, 148, 1383-1391.e6.  | 1.3  | 371       |
| 2  | Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut, 2014, 63, 1943-1950.  | 12.1 | 149       |
| 3  | Lowâ€level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66, 335-343.   | 7.3  | 144       |
| 4  | Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut, 2017, 66, 323-329.   | 12.1 | 125       |
| 5  | Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. Journal of Hepatology, 2017, 67, 1274-1280.   | 3.7  | 120       |
| 6  | Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation:<br>Risk Factors and Clinical Significance. Radiology, 2015, 276, 274-285.   | 7.3  | 113       |
| 7  | Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients<br>with low viral load. Hepatology, 2015, 62, 694-701.   | 7.3  | 106       |
| 8  | Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for<br>Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults.<br>American Journal of Gastroenterology, 2012, 107, 561-567. | 0.4  | 104       |
| 9  | Persistent Nonalcoholic Fatty Liver Disease Increases Risk for Carotid Atherosclerosis.<br>Gastroenterology, 2016, 151, 481-488.e1.   | 1.3  | 95        |
| 10 | High-Mobility Group Box 1 Is Dispensable for Autophagy, Mitochondrial Quality Control, and Organ<br>Function InÁVivo. Cell Metabolism, 2014, 19, 539-547.   | 16.2 | 82        |
| 11 | Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Scientific Reports, 2018, 8, 4718.  | 3.3  | 68        |
| 12 | Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune<br>signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022,<br>14, 1.   | 8.2  | 68        |
| 13 | Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology, 2020, 71, 2023-2032.  | 7.3  | 66        |
| 14 | Nonâ€alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 833-839.   | 2.8  | 66        |
| 15 | Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver International, 2018, 38, 1442-1448.   | 3.9  | 65        |
| 16 | Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS ONE, 2019, 14, e0210730.   | 2.5  | 64        |
| 17 | Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A<br>Multicenter Experience of 45 Cases. Gut and Liver, 2014, 8, 58-63.  | 2.9  | 64        |
| 18 | Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunology, Immunotherapy, 2019, 68, 23-32.  | 4.2  | 62        |

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Nonâ€alcoholic fatty liver diseases and risk of colorectal neoplasia. Alimentary Pharmacology and<br>Therapeutics, 2017, 45, 345-353.   | 3.7  | 54        |
| 20 | The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver International, 2014, 34, 795-801.  | 3.9  | 51        |
| 21 | The recommended treatment algorithms of the <scp>BCLC</scp> and <scp>HKLC</scp> staging systems:<br>does following these always improve survival rates for <scp>HCC</scp> patients?. Liver International,<br>2016, 36, 1490-1497. | 3.9  | 51        |
| 22 | Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. Journal of Hepatology, 2015, 62, 1112-1121.  | 3.7  | 50        |
| 23 | Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C<br>Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. PLoS ONE, 2014, 9, e112184.                             | 2.5  | 49        |
| 24 | Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein<br>Thrombosis: A Propensity Score Analysis. PLoS ONE, 2016, 11, e0154986.   | 2.5  | 48        |
| 25 | The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. Journal of Clinical Lipidology, 2016, 10, 289-298.                 | 1.5  | 47        |
| 26 | Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World Journal of Gastroenterology, 2012, 18, 679.   | 3.3  | 47        |
| 27 | Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. European Journal of Endocrinology, 2019, 181, 185-192.  | 3.7  | 46        |
| 28 | Liver Function Assessment Using Albumin–Bilirubin Grade for Patients with Very Early-Stage<br>Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Digestive Diseases and Sciences,<br>2017, 62, 3235-3242.             | 2.3  | 44        |
| 29 | Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the<br>Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. PLoS ONE, 2015, 10, e0124434.                         | 2.5  | 43        |
| 30 | Nonâ€invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis<br>B patients with lowâ€level viremia. Liver International, 2018, 38, 68-75.  | 3.9  | 42        |
| 31 | Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 250-258.  | 8.9  | 42        |
| 32 | Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clinical and Molecular Hepatology, 2020, 26, 516-528.   | 8.9  | 42        |
| 33 | Monotherapy with tenofovir disoproxil fumarate for multiple drugâ€resistant chronic hepatitis B:<br>3â€year trial. Hepatology, 2017, 66, 772-783.   | 7.3  | 37        |
| 34 | Disease progression and the risk factor analysis for chronic hepatitis C. Liver International, 2008, 28, 1363-1369.   | 3.9  | 35        |
| 35 | Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From<br>Tenofovir Disoproxil Fumarate. Clinical Gastroenterology and Hepatology, 2022, 20, 427-437.e5.                                     | 4.4  | 33        |
| 36 | Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut, 2016, 65, 1721-1732.  | 12.1 | 31        |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World<br>Practice in Korea. Liver Cancer, 2021, 10, 52-62.   | 7.7 | 30        |
| 38 | Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. Liver International, 2012, 32, 937-944.   | 3.9 | 29        |
| 39 | Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. Atherosclerosis, 2014, 234, 270-275.  | 0.8 | 29        |
| 40 | Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. Journal of Hepatology, 2019, 71, 35-44.  | 3.7 | 29        |
| 41 | Transcatheter arterial chemoembolization and radiation therapy for treatment-naÃ <sup>-</sup> ve patients with<br>locally advanced hepatocellular carcinoma. Radiation Oncology Journal, 2014, 32, 14.   | 1.5 | 28        |
| 42 | Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A<br>nationwide cohort study. Journal of Viral Hepatitis, 2020, 27, 896-903.  | 2.0 | 26        |
| 43 | Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget, 2016, 7, 47794-47807.  | 1.8 | 24        |
| 44 | Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. European Radiology, 2016, 26, 3437-3446.  | 4.5 | 24        |
| 45 | Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort<br>study. Hepatology, 2022, 76, 1746-1754.  | 7.3 | 24        |
| 46 | Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. Journal of<br>Gastroenterology and Hepatology (Australia), 2017, 32, 1100-1106.   | 2.8 | 23        |
| 47 | Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular<br>Carcinoma Undergoing Chemoembolization. Digestive Diseases and Sciences, 2018, 63, 1062-1071.  | 2.3 | 23        |
| 48 | Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 477-486.   | 8.9 | 23        |
| 49 | A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic<br>Hepatitis B and Normal Alanine Aminotransferase Levels. Gut and Liver, 2017, 11, 528-534.  | 2.9 | 22        |
| 50 | Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Liver International, 2015, 35, 2363-2369.   | 3.9 | 21        |
| 51 | Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy<br>for multiple small hepatocellular carcinoma within the Milan criteria. Annals of Surgical Treatment<br>and Research, 2020, 99, 238.                       | 1.0 | 20        |
| 52 | Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue<br>failure in chronic hepatitis B patients. Korean Journal of Internal Medicine, 2015, 30, 32.   | 1.7 | 19        |
| 53 | Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From<br>Male Than Female Living Donors. Annals of Surgery, 2018, 268, 1043-1050.   | 4.2 | 18        |
| 54 | Long-term real-world entecavir therapy in treatment-naÃ <sup>-</sup> ve hepatitis B patients: base-line hepatitis B<br>virus DNA and hepatitis B surface antigen levels predict virologic response. Korean Journal of<br>Internal Medicine, 2017, 32, 636-646. | 1.7 | 17        |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Hepatitis B virus DNA levels and overall survival in hepatitis Bâ€related hepatocellular carcinoma patients with lowâ€level viremia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2028-2035.   | 2.8 | 17        |
| 56 | Percutaneous Radiofrequency Ablation of Small (1–2 cm) Hepatocellular Carcinomas Inconspicuous<br>on B-Mode Ultrasonographic Imaging: Usefulness of Combined Fusion Imaging with MRI and<br>Contrast-Enhanced Ultrasonography. Canadian Journal of Gastroenterology and Hepatology, 2018,<br>2018, 1-9. | 1.9 | 16        |
| 57 | Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma. Radiation<br>Oncology Journal, 2018, 36, 25-34.   | 1.5 | 16        |
| 58 | Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.<br>Gut and Liver, 2016, 10, 939-947.  | 2.9 | 15        |
| 59 | Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. World Journal of Gastroenterology, 2016, 22, 3785.   | 3.3 | 15        |
| 60 | Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatology International, 2021, 15, 892-900.   | 4.2 | 15        |
| 61 | Laparoscopic Liver Resection of Hepatocellular Carcinoma with a Tumor Size Larger Than 5 cm: Review of 45 Cases in a Tertiary Institution. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2017, 27, 799-803.  | 1.0 | 14        |
| 62 | Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. International Journal of Epidemiology, 2020, 49, 1562-1571.   | 1.9 | 14        |
| 63 | Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty<br>liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, e529-e534.  | 1.6 | 14        |
| 64 | Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. Digestive and Liver Disease, 2021, 53, 1004-1010.  | 0.9 | 14        |
| 65 | Metabolically-healthy obesity is associated with higher prevalence of colorectal adenoma. PLoS ONE, 2017, 12, e0179480.   | 2.5 | 14        |
| 66 | Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by<br>Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. Gut and Liver, 2016, 10, 295.  | 2.9 | 14        |
| 67 | Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained<br>Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut and Liver, 2016, 10,<br>796-802.  | 2.9 | 14        |
| 68 | Alcohol Intake and Mortality in Patients With Chronic Viral Hepatitis: A Nationwide Cohort Study.<br>American Journal of Gastroenterology, 2021, 116, 329-335.  | 0.4 | 14        |
| 69 | Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly<br>Diagnosed Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 3354-3362.   | 2.3 | 13        |
| 70 | Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk<br>predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy. European<br>Journal of Gastroenterology and Hepatology, 2018, 30, 1447-1452.                             | 1.6 | 13        |
| 71 | Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a<br>Population-based, Matched Case-control Study. Journal of Korean Medical Science, 2018, 33, e264.  | 2.5 | 13        |
| 72 | Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. Journal of Viral Hepatitis, 2021, 28, 1392-1399.   | 2.0 | 13        |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clinical and Molecular Hepatology, 2017, 23, 42-50.  | 8.9 | 13        |
| 74 | Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. Scientific Reports, 2022, 12, 7647.   | 3.3 | 13        |
| 75 | The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. Clinical and Molecular Hepatology, 2014, 20, 283.  | 8.9 | 12        |
| 76 | Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. Journal of Korean Medical Science, 2015, 30, 1618.  | 2.5 | 12        |
| 77 | Nonâ€alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1053-1058.   | 2.8 | 12        |
| 78 | Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. PLoS ONE, 2019, 14, e0213547.  | 2.5 | 12        |
| 79 | Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT)<br>for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase<br>Il trial. Oncotarget, 2017, 8, 52651-52664. | 1.8 | 12        |
| 80 | Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Hepatology International, 2013, 7, 1010-1018.  | 4.2 | 11        |
| 81 | Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. BMC Cancer, 2019, 19, 286.   | 2.6 | 11        |
| 82 | Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C<br>hepatocellular carcinoma in Korea. Korean Journal of Internal Medicine, 2020, 35, 65-78.   | 1.7 | 11        |
| 83 | Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable<br>Serum HBV DNA Levels. Digestive Diseases and Sciences, 2022, 67, 4565-4573.  | 2.3 | 11        |
| 84 | The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A<br>Nationâ€wide Cohort Study. Hepatology, 2021, 74, 2988-2997.   | 7.3 | 10        |
| 85 | Occult hepatitis B virus infection in chronic hemodialysis patients in Korea.<br>Hepato-Gastroenterology, 2008, 55, 1721-4.  | 0.5 | 10        |
| 86 | Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis<br>B Surface Antigen Seroclearance. Clinical and Translational Gastroenterology, 2021, 12, e00290.  | 2.5 | 9         |
| 87 | Nonlinear tumor evolution from dysplastic nodules to hepatocellular carcinoma. Oncotarget, 2017,<br>8, 2076-2082.  | 1.8 | 8         |
| 88 | Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigenâ€negative, core<br>antibodyâ€positive recipients. Journal of Viral Hepatitis, 2020, 27, 739-746.  | 2.0 | 8         |
| 89 | Survival in untreated hepatocellular carcinoma: A national cohort study. PLoS ONE, 2021, 16, e0246143.   | 2.5 | 8         |
| 90 | Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clinical and Molecular Hepatology, 2015, 21, 232.  | 8.9 | 7         |

| #   | Article   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis. Medicine<br>(United States), 2016, 95, e2578.   | 1.0 | 6         |
| 92  | Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT)<br>for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective<br>phase II trial. International Journal of Hyperthermia, 2016, 32, 331-338. | 2.5 | 6         |
| 93  | Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial<br>Chemoembolization for Hepatocellular Carcinoma. Yonsei Medical Journal, 2021, 62, 12.   | 2.2 | 6         |
| 94  | Clinical impact of healthcare-associated acquisition in cirrhotic patients with community-onset spontaneous bacterial peritonitis. Korean Journal of Internal Medicine, 2020, 35, 215-221.  | 1.7 | 6         |
| 95  | Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. BMC Medicine, 2022, 20, 18.  | 5.5 | 6         |
| 96  | Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. Scandinavian Journal of Gastroenterology, 2018, 53, 727-733.   | 1.5 | 5         |
| 97  | Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Digestive Diseases and Sciences, 2021, 66, 2816-2825.  | 2.3 | 5         |
| 98  | Longâ€ŧerm hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean<br>patients—Functional cure unlikely. Journal of Viral Hepatitis, 2020, 27, 951-954.   | 2.0 | 5         |
| 99  | Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS ONE, 2015, 10, e0144777.  | 2.5 | 5         |
| 100 | Clinical Impact of the Development of YMDD Mutants in Hepatitis B Virus-Associated<br>Glomerulonephritis. Hepato-Gastroenterology, 2011, 58, 1291-1295.   | 0.5 | 5         |
| 101 | The correlation of hepatitis B virus pre-S mutation with mitochondrial D-loop mutations and common deletions in hepatocellular carcinoma. Hepato-Gastroenterology, 2011, 58, 522-8.   | 0.5 | 5         |
| 102 | Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea.<br>Korean Journal of Internal Medicine, 2022, 37, 1082-1087.   | 1.7 | 5         |
| 103 | A comparison of clevudine and entecavir for treatment-naÃ <sup>-</sup> ve patients with chronic hepatitis B:<br>results after 2Âyears of treatment. Hepatology International, 2013, 7, 106-110.   | 4.2 | 4         |
| 104 | Relationship of Liver Stiffness and Controlled Attenuation Parameter Measured by Transient<br>Elastography with Diabetes Mellitus in Patients with Chronic Liver Disease. Journal of Korean Medical<br>Science, 2014, 29, 1113.   | 2.5 | 4         |
| 105 | Inclusive Quantification Assay of Serum Desâ€Î³â€Carboxyprothrombin Proteoforms for Hepatocellular<br>Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatology Communications, 2021, 5, 1767-1783.  | 4.3 | 4         |
| 106 | Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein. Clinical and Molecular Hepatology, 2015, 21, 393.   | 8.9 | 4         |
| 107 | The correlation of hepatitis B virus pre-S mutation with cellular oxidative DNA damage in hepatocellular carcinoma. Hepato-Gastroenterology, 2008, 55, 2028-32.   | 0.5 | 4         |
| 108 | Weight Change and Development of Subclinical Carotid Atherosclerosis Among Metabolically Healthy<br>Adults: A Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e410-e416.   | 3.6 | 3         |

| #   | Article  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels.<br>World Journal of Gastroenterology, 2013, 19, 2256.   | 3.3 | 3         |
| 110 | Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scandinavian Journal of Gastroenterology, 2021, , 1-8.   | 1.5 | 3         |
| 111 | A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. Digestive and Liver Disease, 2021, 53, 210-215.  | 0.9 | 2         |
| 112 | Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. Korean Journal of Transplantation, 2021, 35, 24-32.   | 0.1 | 2         |
| 113 | Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. Digestive Diseases and Sciences, 2015, 60, 3794-3800.  | 2.3 | 1         |
| 114 | Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. PLoS ONE, 2021, 16, e0255624.   | 2.5 | 1         |
| 115 | Letter: <i>Helicobacter pylori</i> -related non-alcoholic fatty liver disease with concomitant<br>metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. Alimentary Pharmacology<br>and Therapeutics, 2017, 45, 577-578.               | 3.7 | 0         |
| 116 | Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With<br>Hepatocellular Carcinoma. Transplantation Proceedings, 2020, 52, 881-888.  | 0.6 | 0         |
| 117 | Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential<br>implications for surveillance goal. Scandinavian Journal of Gastroenterology, 2021, 56, 274-280.   | 1.5 | 0         |
| 118 | Comparison of Mac-2 Binding Protein Glycosylation Isomer, Fibroscan, and Other Fibrosis Markers for<br>Assessing Liver Cirrhosis in Patients with Chronic Hepatitis B Virus-mediated Hepatocellular<br>Carcinoma. Laboratory Medicine Online, 2020, 10, 109. | 0.2 | 0         |
| 119 | Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development.<br>Scandinavian Journal of Gastroenterology, 0, , 1-8.   | 1.5 | 0         |